Regeneron and Sanofi Announce Kevzara(R) (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA

New action date for Kevzara U.S. BLA is May 22, 2017 TARRYTOWN, N.Y. and PARIS, April 28, 2017 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administra... Biopharmaceuticals Regeneron Pharmaceuticals, Sanofi, Kevzara, sarilumab, rheumatoid arthritis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news